Since you brought up the topic of the new investors from the S-1...,have you seen these two "losers"(sarcasm infused) who were included...
-ROBERT F. JOHNSTON-Warrants for over 8.5 Million AMBS shares: Bob Johnston founded Johnston Associates Inc. in 1968 to provide merger advisory and financing for emerging companies in technology-intensive industries. In the mid-70s, he directed his efforts toward biotechnology and health care. He founded Cytogen, Ecogen, Sepracor, i-STAT, Envirogen, and Praelux (formerly SEQ), and was instrumental in the early formations of Sonomed, Biocyte, Immunicon, and VelaPharm. Prior to starting Johnston Associates, Bob was an investment banker for F.S. Smithers & Co. and for Smith Barney & Co. in New York. He received his B.A. from Princeton University and his M.B.A. from New York University.
BILAL BASRAI Managing Director - Investment Banking at Zack's -also listed on the S-1 as issued warrants for almost 6,000,000 AMBS shares.
Bilal Basrai is the Managing Director and head of investment banking at Zacks & Company, where he oversees the firm’s investment banking and capital markets efforts. Prior to joining Zacks, Bilal was most recently Director of the Corporate Finance Group at C.K. Cooper & Company, a research-driven, institution-focused, investment banking boutique, providing the full range of capital market and advisory services to public and private companies. At C.K. Cooper & Company, he was the team leader on corporate finance assignments with the firm’s Healthcare clients, which included appraisals, fairness opinions, merger and acquisition advice, licensing agreements and capital formation.
Bilal spent the majority of his career in New York City covering the Health Care Services sector with leading investment banks including Salomon Smith Barney, UBS Financial, and Lehman Brothers. He also spent two years with the Stanford Financial Group in South Florida, prior to co-founding Iliad Advisors, LLC in 2006, a boutique investment advisory firm. Bilal has been involved in over $4.5 billion worth of transactions in the Healthcare sector over his Wall Street career.
Bilal has also been a top-ranked analyst for the majority of the Healthcare stocks that he has covered during his days as an equity research analyst and has generated an excess industry return of 11.1%, according to analyst ranking agency Starmine Monitor. The agency has ranked him as the seventh best stock-picker in the Healthcare Services & Providers Industry
Not too shabby, huh?
